Translating Advanced Cancer Research into Personalized, Compassionate Care
Saint John’s Cancer Institute is renowned research facility dedicated to advanced therapeutics, translational sciences, and best medical practices. We promote robust fellowship programs and clinical trials, collaborating with industry and academic partners worldwide.Read More
Innovation Starts Here
Saint John’s Cancer Institute (SJCI) is a pioneer in drug discovery, therapeutics, clinical trials, and research. SJCI established the Sentinel Lymph Node Biopsy under the late Dr. Donald L. Morton, which has become the standard of lymph node care for melanoma and breast cancer worldwide.
Today, our patients continue to have access to innovative treatments, therapeutics, and trials. We are at the forefront of understanding the biology of cancer as well as expanding treatment for under-served communities.Learn More
Treating recurrent glioblastoma with electronic Interoperative Radiation Therapy (IORT)
“…an incredible achievement for everyone involved, especially for PNI and our Saint John’s Cancer Institute.”
– Michael Ricks, Providence Saint John’s Chief Executive
Learn more about PNI: Visit Pacific Neuroscience Institute
Press Release: Saint John’s first in the nation to treat glioblastoma patient with revolutionary radiation therapy – Providence
A Legacy of Research Excellence
“He was ahead of his peers in anticipating the genetics era of cancer research, for decades he carefully maintained archival specimen resource for correlative translational studies.”
– Laura Morton Rowe, Chief Human Resources Officer, Saint John’s Health Center
Providence Saint John’s Health Center contributes $2 million to Stand Up To Cancer Dream Team’s Effort to Reduce Disparities in Colorectal Cancer Screenings
Co-leading the Dream Team is Dr. Anton Bilchik
“This team has a tremendous opportunity to create solutions that can be used as national models for integrated colorectal cancer outreach and screening.”
– Anton Bilchik, M.D.
RFA Treatment for Benign Thyroid Nodules
“We are now one of the only centers in the Southwest and Westcoast to offer this new procedure for patients.”
– Melanie GoldFarb, M.D.
Center of Excellence: Endocrine – Saint John’s Cancer Institute
Press Release: Thyroid RFA, a first for Providence, gives patients a non-surgical treatment pathway at Saint John’s Health Center – Providence
Breast Surgical Oncology Fellowship
The Breast Surgical Oncology Fellowship at the Saint John’s Cancer Institute provides a diverse and comprehensive exposure to the multidisciplinary aspects of breast cancer care and benign breast disease over a one-year time period with a potential second year for continuation of clinical or basic science research.LEARN MORE ABOUT THIS FELLOWSHIP
Donald L. Morton Complex General Surgical Oncology Fellowship
With a longstanding history of excellence in multidisciplinary cancer care and research, the Saint John’s Cancer Institute continues its legacy in surgical oncology through the Donald L. Morton Complex General Surgical Oncology Fellowship.Learn more about this fellowship
Postdoctoral Lab-Based Translational Molecular Medicine Fellowship
As pioneers in translational studies on “liquid biopsies” involving circulating tumor cells in multiple types of solid tumors, the fellowship program also consists of studying epigenetic mechanisms regulating solid tumor as well as pharmacogenomics and immunogenomic based prediction of response to therapy.Learn more about this fellowship
This training program focuses on endonasal endoscopic and keyhole surgical approaches, neuro-endoscopy, pituitary tumor management and multimodality neuro-oncology treatments.Learn more about this fellowship
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Przemyslaw W. Twardowski, M.D., and his colleagues, have published a new study in the New England Journal of Medicine, which demonstrates significant benefit of therapy with olaparib (PARP inhibitor) in patients with advanced prostate cancer who harbor certain mutations of DNA repair system and who failed standard treatments. Based on the results of that study on 5/19/2020 Food and Drug Administration (FDA) granted approval of olaparib, providing a valuable treatment option for about 25% of patients with advanced prostate cancer with certain mutations of DNA repair. These mutations can be detected by performing an analysis of a patient’s cancer specimen and sometimes also on a specialized blood test.
ANG1005, a Brain Penetrating Peptide-Drug Conjugate, Shows Activity in Patients With Breast Cancer With Leptomeningeal Carcinomatosis and Recurrent Brain Metastases
The department of Translational Neurosciences studied ANG1005, a novel taxane derivative, which consists of 3 paclitaxel molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via LRP1 transport system. Read the publication to learn the results.
Prognostic Impact and Utility of Immunoprofiling in the Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC)
This is the first study to assess the utility of subtypes of T cells as prognostic markers in patients with colorectal peritoneal carcinomatosis, which may play a role in patients with low-volume disease. The purpose of this study is to evaluate immune profiles of patients with peritoneal carcinomatosis and their correlation with overall survival (OS).